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This article provides an overview on the application of metallic ions in the ﬁelds of rege-
nerative medicine and tissue engineering, focusing on their therapeutic applications and
the need to design strategies for controlling the release of loaded ions from biomaterial
scaffolds. A detailed summary of relevant metallic ions with potential use in tissue engineer-
ing approaches is presented. Remaining challenges in the ﬁeld and directions for future
research efforts with focus on the key variables needed to be taken into account when
considering the controlled release of metallic ions in tissue engineering therapeutics are
also highlighted.
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1. INTRODUCTION
A common tissue engineering approach involves the
development of novel biomaterials to produce three-
dimensional porous scaffolds, that encourage cell
inﬁltration and proliferation for tissue regeneration
[1–3]. Several debilitating and deadly conditions such
as osteoporosis, osteoarthritis, retinopathy, burns, myo-
cardial infarction as well as tendon and ligament
defects, among others have the potential to be treated
by tissue engineering strategies. Scaffolds made from bio-
degradable polymers, ceramics or their composites are
popular choices for tissue engineering applications and
there are increasing investigations focusing on loading
engineered scaffolds with therapeutic drugs, generating
a dual function for the matrices: scaffolds for the
growth of new tissue and carriers for controlled in situ
drug delivery [4–13]. In addition, there is growing inter-
est in developing matrices with the capacity to induce
speciﬁc interactions within cells in order to unlock the
innate path for self-repair [14]. Further, it is worthwhile
noting the current expansion of the ﬁeld of therapeu-
tic tissue engineering (TTE), which considers the
enhancement of the functionality of scaffolds by incor-
porating a drug delivery function with therapeutic
effectiveness [12,15]. In this context, in order to design
and develop TTE scaffolds, several variables have to be
taken into account. From a tissue engineering perspec-
tive, selection of suitable processing methods that
provide the best mechanical and structural properties
to the ﬁnal porous scaffold is of highest relevance [16].
From a pharmaceutical perspective, the scaffold fabrica-
tion method must be compatible with drug stability and
sustained drug release; conditions such as high tempera-
ture, use of some organic solvents, pressure and free
radicalsthat may lead to drug decomposition will restrict
the selection of fabrication processes [17]. There are sev-
eral otherwise very convenient fabrication techniques
for tissue engineering scaffolds, involving however,
processes that are incompatible with the incorporation
and stability of organic drugs [12]. It is therefore attrac-
tive to explore the use of metallic ions as therapeutic
agents (MITAs) within the scope of TTE. A wide range
of MITA, the majority of them being essential cofactors
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cobalt, copper, gallium, iron, manganese, silver, stron-
tium, vanadium and zinc, and will be discussed further
in this article. The use of MITA does not pose the risk
of decomposition or instability, which is intrinsic to
organic molecules. Further, the unique properties of
MITA with therapeutic signiﬁcance (e.g. hydrolytic and
redox activity, Lewis acidity, electrophilicity, valency,
geometry, magnetic effect, spectroscopy, radiochemical
properties) indicate the ability of these ions to interact
with other ions that can alter cellular functions, cell
metabolism or biological functions, by binding to macro-
molecules such as enzymes and nucleic acids, and/or
activating ion channels or secondary signalling [17].
These actions of MITA may provide effects that are
different from those that can be achieved through other
chemical, biochemical or genetic manipulations [17]. In
addition, an MITA approach is usually economic and
stableundertypicalprocessingconditionsforbiomaterial
scaffold production,which may involve the useof organic
solvents, high temperatures, pressure and free radicals.
Nevertheless, the potential toxicity of metallic ions
when delivered locally has to be taken into account.
Fromthisperspective,thepurposeofthisreviewistopro-
vide anoverview oftheadvancesintheexpandingﬁeldof
application of metallic ions in regenerative medicine and
tissue engineering, focusing on their therapeutic appli-
cations. Particular emphasis is given to bone tissue
engineering (TE), as this particular TE area seems to
be the more developed regarding the use of MITA (also
named bioinorganics [18]). This article is not encyclopae-
dic; rather, selected examples have been chosen to
illustrate and summarize the progress in the research
ﬁeld. In addition, some works that detail the use of
MITA to regulate speciﬁc metabolic processes are
included despite not yet being used in tissue engineering,
but with the potential to be considered in future TE
strategies. The article is organized in the following
manner: §2 discusses the general local release of metallic
ions and their interaction with metabolic processes, §3
focuses on the key variables needed to be taken into
account when considering the inclusion of MITA in con-
trolled drug delivery systems in general and in scaffolds
for tissue engineering in particular. Finally, remaining
challenges in the ﬁeld and directions for future research
efforts are highlighted in §4.
2. LOCALIZED RELEASE OF
METALLIC IONS
In the body, various metallic ions act as cofactors of
enzymes and stimulate a chain of reactions associated
with cell signalling pathways towards tissue equilibrium
[19]. These properties, far from speciﬁc, are reﬂected in
the very wide range of pathological conditions in which
metallic ions are involved. Interactions with metallic
ions play important roles in a variety of diseases and
metabolic disorders such as cancer, central nervous
system disorders, infectious diseases, perturbation of
gastrointestinal activity and endocrine disorders;
studies based on the effects of metallic ions in a wide
range of pathologies are reviewed in the literature
[17,20]. Thus, the efﬁciency and selectivity of the thera-
peutic effect of metallic ions can be improved by
controlling the precise level and/or location of them in
the body. In addition, the ionic states of certain metallic
ions are unstable, and they may have toxic effects when
directly ingested. To overcome these disadvantages,
extensive research has been conducted to develop
matrices to control the local release of metallic ions.
Current metallic-ion-based drugs are prone to lead to
signiﬁcant systemic toxicity; thus, the design of
matrices for the local delivery of relatively high concen-
trations of metallic-ion-based drugs to target tissues
with reduced systemic adverse effects is of high interest.
The degree of metallic ion loading into matrices for
local delivery and the controlled and sustained release
of the loaded ions are undoubtedly important to ulti-
mately optimize metal ion delivery for therapeutic
use. In addition, it is imperative to control the release
rate of loaded ions. Nevertheless, ascertaining the
appropriate degree of metallic ion loading and the
appropriate amount released in a determined period is
difﬁcult because therapeutic levels of most MITA are
unknown. A strategy very often used to load metallic
ions into matrices is to bind them to a suitable sub-
strate (zeolites, hydroxyapatite, bioactive glass, silica,
carbon ﬁbres) so that the stability of ionic states is
improved and the ions can be released over a long
period of time with potential applications in many
ﬁelds [21–32]. Despite the efforts made in this respect,
the achievements in controlling and sustaining the
release of loaded therapeutic metal ions—in terms of
obtaining constant therapeutic amount release of the
ion over a period of time—have been very limited [18].
Amorphous peroxititanates (APT) might also be used
to bind a variety of metal compounds with high-afﬁnity
forming complexes to control the delivery of metal-
based drugs to the target tissue avoiding systemic
toxicity, or to capture metal ions from body tissues
[33–37]. Wataha et al.[ 33] demonstrated that metal–
APT complexes facilitate metal ion delivery (such as
gold and platinum) to monocytes as well as ﬁbroblasts.
Despite the improvements made in controlling ion
release from a variety of biomaterials, potential
accumulation and toxicity require further research. In
healthy systems, free metallic ion concentrations are
maintained at very low levels, and the normal metal
metabolism delivers them in a selective manner to
their sites of action, while maintaining rigid control
over their reactivity. However, anomalous metallic ion
metabolism can contribute to pathological states such
as haemochromatosis, Wilson disease and Menkes
disease [38–40]. Moreover, as mentioned above, the
singular properties of metallic ions, such as Lewis
acidity, hydrolytic and redox activity, electrophilicity
and valency, can alter cellular activities supporting
the cell metabolism or, in the worse case scenario, indu-
cing toxic effects. For example, minimal shortages of
certain metallic ions are involved in the pathogenesis
of various chronic diseases such as diabetes mellitus,
rheumatoid arthritis, coronary heart disease, epilepsy,
nephropathy and a variety of bone-related pathologies
[41–45]. By contrast, the uncontrolled release of metal
ions may produce adverse effects such as the case of
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of signiﬁcant amounts of metal ions into the tissues
in close contact with the implant and the systemic
circulation, often resulting in complications such as
inﬂammatory and immune reactions [46–48]. The
actions of MITA loaded within matrices for local release
in general, and within scaffolds for tissue engineering in
particular, may be different from those that can be
achieved through other chemical, biochemical or genetic
interactions. The local actions of MITA within the
environment in which they are released are presumed
to differ in general from the actions of non-metallic
agents, offering singular therapeutic opportunities. On
the other hand, it is important to gain control over
the potential toxicity of MITA, and the appropriate
therapeutic concentrations for local release must be
deﬁned. In this context and considering the growing
interest in the local release of metallic ions for thera-
peutic purposes, the following issues must be taken
into consideration: (i) reactions of metallic ions with
cellular constituents (e.g. proteins, nucleic acids—
DNA and RNA—lipids, carbohydrates, redox sub-
strates, signalling molecules); (ii) reactions of metallic
ions in the local cellular environment; (iii) incorporation
of metallic ions into cells and delivery to speciﬁc orga-
nelles and cellular structures; and (iv) interactions of
metallic ions with speciﬁc receptors and enzymes and
their involvement in metabolic pathways to alter cell
functions [49,50].
3. THERAPEUTIC IONS IN
TISSUE ENGINEERING
The interest in the application of MITA in the ﬁeld of
regenerative medicine and TE scaffold development is
growing owing to the fact that MITA may offer thera-
peutic opportunities coupled with high ﬂexibility to
be incorporated in engineered biomaterial scaffolds by
a broad range of processing methods. Moreover,
MITA have lower cost, higher stability and potentially
greater safety than recombinant proteins or genetic
engineering approaches [50]. Table 1 summarizes the
most common processes reported to produce scaffolds
for tissue engineering with the potential to be used
for the incorporation of MITA in scaffolds. Processing
techniques such as rapid prototyping, electrospinning,
thermally induced phase separation and solid free
form fabrication are attractive because they enable
fabrication of engineered three-dimensional, porous
structures of high uniformity and reproducibility
[81–89]. Additionally, organic/inorganic composite
scaffolds, particularly for bone tissue engineering appli-
cations, made of bioceramics or bioactive glasses and
biodegradable polymers [16], often include metallic
ions as part of the bioceramic or bioactive glass struc-
tural composition. These inorganic materials enable
metal ion release during their degradation in vitro or
in vivo [18,32]. For example, when bioactive glass (e.g.
45S5 Bioglass) [90] is used in scaffolds for bone tissue
engineering and introduced to ﬁll a bone defect, critical
concentrations of soluble Si, Ca, P and Na ions are
released, with the capability to produce both
intracellular and extracellular effects at the interface
between the glass and the cellular environment
[32,60,91–101]. These ions are known to stimulate var-
ious processes; for example, several investigations have
demonstrated that released ions from bioactive glasses
are able to induce gene expression with known roles in
processes related to bone metabolism by signal trans-
duction, thereby enhancing cell differentiation and
osteogenesis [91,94,95,102]. The ionic dissolution
products of bioactive glasses can also promote angio-
genesis [103]. It is, therefore, vital that the kinetics of
ion release from any scaffold (or implant) made from
bioceramics can be tailored and controlled [18]. A com-
prehensive review about the biological response to ionic
dissolution products from glass–ceramics and bioactive
glasses in the context of bone tissue engineering has
been recently published [32]. Nevertheless, it is impor-
tant to highlight that few studies are focused on
developing ideal matrices for the control and sustained
release of loaded ions within speciﬁc therapeutic levels,
over a previously deﬁned period of time. Several
attempts to intentionally load therapeutic metal ions
rely on ion substitution in ceramic systems, limiting
the possibility to control and sustain the release of a
speciﬁc therapeutic dose over a period of time. In this
sense, the application of inorganic ions in the ﬁeld of
bone regeneration, with special emphasis on the lack
of a controlled, sustained and localized release of both
structural and non-structural ions from bioceramics, is
discussed in a recent report of Habibovic & Barralet
[18]. Novel strategies are based on biodegradable
metals, such as magnesium alloys and iron, which are
dissolved in vivo when no longer needed [104]. In this
regard, research activities are underway to make biode-
gradable metals practical for tissue engineering [105].
There are also new techniques to produce degradable
metallic implants, innovative coating technologies to
yield special surface functionalities, new biodegradable
materials and methods to develop nano-devices for
monitoring implants and sensing functions [104,106–
113]. In addition, the use of metallic ions as cross-linkers
of polymers in the formation of hydrogels and as net-
work formers or modiﬁers of bioactive glasses (silicate
or phosphate systems) in the elaboration of bioactive
scaffolds are being increasingly investigated [13,32,51,
114–118]. Figure 1 provides a summary of the most
common speciﬁc targets of relevant metallic ions
reviewed in the present work in their role as therapeutic
agents. Table 2 summarizes relevant functions and
biological effects of metallic ions with promising appli-
cations in tissue engineering. As indicated above, one
of the obvious negative effects of the localized release
of ions could be potential ion accumulation and tox-
icity. It is, therefore, vital that the kinetic of ion
release from any scaffold is tailored. Several investi-
gations have shown how the incorporation of
speciﬁc metallic ions in different matrices could affect
(usually improve) the physiology and metabolism of
cells close to the release area; a summary of previous
investigations is presented in table 3. The list is
intended to be illustrative, not exhaustive. The
number of speciﬁc investigations on effects of MITA
intentionally added to scaffolds for therapeutic
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J. R. Soc. Interface (2012)purposes, aimed at engineering a wide range of tissues,
is continuously growing. Particularly, in the case of
bone TE, there is increasing interest in the role of cer-
tain metallic ions (e.g. copper, strontium and zinc) in
bone pathologic states because many of them are cofac-
tors in metabolic processes involving bone, articular
tissues and immune system functions [43,246]. Further,
the loading of MITA within scaffolds lacks the risk of
drug decomposition or instability depending on the
employed processes of fabrication, as explained above.
Moreover, bacterial adhesion to biomaterials that
causes biomaterial-centred infection and poor tissue
integration are problems that could limit the viability
of the scaffold, especially when it is designed to be
applied in vivo (as opposed to applications in bio-
reactors, for example) [91]. As mentioned above, there
is growing interest in exploring the possibility of using
the device itself to deliver therapeutic drugs to prevent
possible bacterial colonization of the device following
implant surgery and/or pro-angiogenic agents to
Table 1. Summary of the most common processes reported to fabricate scaffolds for tissue engineering with capabilities to
include metallic ions.
technique characteristics reference
melt mouldingþion-exchange melting and sintering at high temperatureþintroduction of ions by
ion-exchange process
[51]
solvent casting scaffolds are prepared by dissolving/suspending polymers/ceramics in
presence of porogens (such as sodium chloride, sugar crystals). After
pouring the mixture into a mould, solvents are removed either by
evaporation or vacuum/freeze drying. Porosity is achieved by dissolving
the porogens in water. Finally, the porous materials are usually lyophilized
[52,53]
freeze drying scaffolds are prepared by dissolving/suspending polymers/ceramics in water
or in an organic solvent followed by emulsiﬁcation with a water phase.
After pouring the mixture into a mould, solvents are removed by freeze




scaffolds are prepared by dissolving/suspending polymers/ceramics in a
solvent that freezes below the phase separation temperature of the polymer
solution. Porous materials are obtained by subsequent freeze drying
[55]
foaming effervescent salts (ammonium bicarbonate) are used as porogens and mixed
with an organic viscous solution/suspension of polymer/ceramic. After
solvent evaporation, porosity is achieved by placing scaffolds into hot water
or an aqueous solution of citric acid to dissolve the salts. An alternative is
to use CO2-based gas
[53,56,57]
replica technique scaffolds are prepared by dipping a polyurethane sponge into a slurry of
proper viscosity containing ceramic particles. The impregnation step and
the removal of the exceeding slurry should be tuned in order to obtain,
after the sponge removal, a defect-free porous three-dimensional scaffold.
Sometimes, in order to obtain mesoporous, a tensioactive may be added
to the vehicle
[58,59]
sol–gel scaffolds are prepared by dissolving metallic metal salts or metal organic
compounds in a solvent where a series of hydrolysis and polymeration
reactions allows the formation of a colloidal suspension (‘sol’). After casting
the ‘sol’ into a mould, a wet ‘gel’ is formed. With further drying and heat
treatment, the ‘gel’ is converted into dense ceramic or glass articles
[60,61]
powder compression scaffolds are prepared by compressing polymers/ceramics using projectiles or
punch and dies. The velocity of the projectile or punch and dies is adjusted
to achieve powder consolidation and the desire porosity. It can be followed
by sintering. An alternative is to use uniaxial and isostatic pressure
[62–65]
laser-based processing systems scaffolds are prepared either layer by layer by photopolyermerization of a
liquid (stereolithography) or sintering of powder material (selective laser
syntering). In both cases, material is swept over a build platform that is
lowered for each layer
[66–72]
printing-based systems scaffolds are prepared by printing a chemical binder onto a bed of powdered
material (three-dimensional printing)
[73,74]
electrospinning the material to be electrospun is ﬁrst dissolved in a suitable solvent to obtain
a viscous solution. The solution is passed through a spinneret and a high
voltage is used to charge the solution
[75–77]
nozzle-based systems a thin ﬁlament of material (extruded thermoplastic polymer) that is heated
through a nozzle is printed by a fused deposition modeller. Then, the mould
is negative for the scaffold fabricated via fused deposition modelling
[78–80]
404 Review. Metallic ions as therapeutic agents V. Mourin ˜o et al.
J. R. Soc. Interface (2012)secure vascularization [13,32,91,117,141]. In this con-
text, bacteriostatic effect and pro-angiogenic potential
seem to be the most common aims of the incorporation
of metallic ions within scaffolds to date and the most
common ions studied in this regard are copper, silver,







































































Figure 1. Most common speciﬁc targets of relevant metallic ions in their role of therapeutic agents. VEGF, vascular
endothelial growth factor.
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FUTURE STEPS
Metallic ions are of interest in the ﬁelds of regenerative
medicine and tissue engineering owing to the possibility
of exploiting their unique advantages for therapeutic
applications: reduced cost, increased stability and, in
terms of safety, potentially lesser risk than techniques
of recombinant proteins or genetic engineering. Several
biomaterial-based strategies are being designed for the
controlled-localized delivery of metallic ions and the
ﬁeld is continuously expanding. However, many chal-
lenges remain. First, there is a need to acquire a deep
understanding of the roles of speciﬁc metals in cellular
regulation and cell–cell signalling in both healthy and
diseased tissue when they are released locally from scaf-
folds, implants or other releasing devices. Second, more
in vivo evidence conﬁrming that metallic ions can be
released locally from scaffolds without systemic toxicity
and carcinogenic effects is bound to follow [247].
In addition, broader knowledge about mechanisms link-
ing univocally the improved biological performance
provided by TE scaffolds to the effect of metallic ions
release is also needed. Much of the work is expected
to involve collaborations, including biologists, mate-
rial scientists, pharmaceutical technologists, tissue
engineers and biomedical researchers. A great deal of
further work is necessary but current investigations
suggest that such work may be fruitful towards more
effective tissue engineering strategies with improved
MITA-releasing biomaterials. The ﬁnal objective of
this review has been thus to encourage research that
bridges the areas at the interface between materials
chemistry and medicine for developing new tissue engin-
eering therapeutic strategies based on controlled metal
ion release.
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